Mendoza CU, Alonso BME

Language: Spanish
References: 17
Page: 33-43
PDF size: 273.71 Kb.

ABSTRACT

Introduction: rheumatoid factor is the autoantibody most commonly associated with rheumatoid arthritis. Despite the considerable progress achieved in the study of its pathogenesis, further analysis is required of the relationship between this antibody and coronary risk markers.
Objectives: evaluate the association between rheumatoid factor and the coronary risk markers lipoprotein(a), apolipoprotein B / apolipoprotein A1, LDL / HDL cholesterol, apolipoprotein B / LDL cholesterol, and atherogenic index, as well as the predictive value of this antibody with respect to such markers.
Methods: an observational cross-sectional analytical study was conducted of a sample of patients with rheumatoid arthritis and apparently healthy controls from the province of Matanzas from June 2011 to March 2014. Results were analyzed with the statistical software SPSS.
Results: rheumatoid factor showed an association with atherogenic indices, LDL / HDL cholesterol and apolipoprotein B / LDL cholesterol, as well as usefulness to estimate the first two and predictive value for the atherogenic index irrespective of markers of disease activity: C-reactive protein, C3 complement, C4 complement and DAS28 in patients seropositive for this autoantibody [Pearson r = 0.632; 0.345; (-) 0.359; R2= 0.406; 0.119 (p ‹ 0.05), respectively].
Conclusions: the study showed the relationship, predictive value and possible indirect stratification of coronary risk based on the serum levels of rheumatoid factor IgM in patients with seropositive rheumatoid arthritis. Further examination should be conducted of this scientific problem in reference to autoantibodies associated with autoimmune diseases of high cardiovascular morbidity and mortality.

REFERENCES

1. Mclnnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. The New England Journal of Medicine. 2011;365:2205-19.

2. Prada DM, Rosabal NM, Molinero C, Gómez JA, Hernández IM, López AM, et al. Artritis Reumatoide: Beneficios clínicos observados en pacientes tratados con anticuerpo monoclonal Itulizumab (T1H MAB), 2 años después de recibir tratamiento. Revista Cubana de Reumatología. 2011; 13(17-18):5-13.

3. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology. 2003;42:607-13.

4. Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R. Atherosclerosis and Rheumatoid Arthritis: More than a Simple Association. Mediators of Inflammation. 2012 [citado 10 Jun 2014]. Disponible en: http://scholar.google.com.cu/scholar?hl=es&q=Atherosclerosis+and+rheumatoid+art hritis%3A+More+than+a+simple+Association&btnG=&lr

5. Södergren A, Karp K, Boman K, Eriksson C, Lundström E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Research & Therapy. 2010;12:R158.

6. Soltész P, Kerekes G, Dér H, Szücs G, Szántó S, Kiss E, et al. Comparative assessment of vascular function in autoinmune rheumatic diseases. Considerations of prevention and treatment. Autoimmunity Reviews. 2011;doi:10.1016/j.autrev.2011.01.004.

7. Sarmiento JC, Amaya J, Espinosa JS, Herrera C, Anaya JM, Rojas A, et al. Cardiovascular Disease in Rheumatoid Arthritis: A Systematic Literature Review in Latin America. Arthritis. 2012 [citado 10 Jun 2014]. Disponible en: http://scholar.google.com.cu/scholar?q=cardiovascular+Disease+in+Rheumatoid+Art hritis%3A+A+Systematic+Literature+Review+in+Latin+America&btnG=&hl=es&as_s dt=0%2C5

8. Wallach J. Enfermedades cardiovasculares. En: Centro Nacional de Información de Ciencias Médicas, editor. Interpretación clínica de las pruebas de laboratorio. La Habana: Editorial Ciencias Médicas; 2006. p. 141-67.

9. Prada DM, Santana I, Molinero C, Gómez JA, Milera JM, Hernández MV, et al. Caracterización clínico-epidemiológica y tratamiento precoz en la Artritis Reumatoide temprana. Revista cubana de Reumatología. 2012 [citado 10 Jun 2014];14(21). Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/219

10. Loza E, Calvo J, Del Canto F, Alarcón GS. Enfermedades autoinmunes. En: Artritis Reumatoide. Barcelona: Masson. 2006. p. 369-99.

11. Ráček V, Němec P. Rheumatoid Arthritis – an independent risk factor for cardiovascular disease. Vnitr Lek. 2012;58(11):834-8.

12. Gkaliagkousi E, Gavriilaki E, Doumas M, Pedtidis K, Aslanidis S, Stella D, et al. Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. Journal Clinical Rheumatology. 2012;18(8):422-30.

13. Bartels Ch, Kind A, Everett Ch, Mell M, McBride P, Smith M, et al. Low frequency of primary lipid screening among medicare patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM. 2011;63(5):1221-30.

14. Pieper J, Herrath J, Raghavan S, Muhammad K, Van R, Malmströ-Pieper J, et.al. CTLA4-Ig (abatacept) therapy modulates Tcell effector functions in autoantibodypositive rheumatoid arthritis patients. BCM Immunology. 2013;14:34-43.

15. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology. 2009;48:11-22.

16. Missala I, Kassner U, Steinhagen E. A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis. Int J Rheumatol. 2012 [citado 10 Jun 2014]. Disponible en: http://scholar.google.com.cu/scholar?q=A+Systematic+Literature+Review+of+the+A ssociation+of+Lipoprotein%28a%29+and+Autoimmune+Diseases+and+Atherosclero sis&btnG=&hl=es&as_sdt=0%2C5

17. Mendoza U, Rodríguez JA, Alonso MA. Marcadores de respuesta inflamatoria y riesgo coronario en pacientes con Artritis Reumatoide. Revista cubana de investigaciones biomédicas [Seriada en línea]. 2013 [citado 10 jun 2014];32(3). Disponible en URL: http://bvs.sld.cu/revistas/ibi/vol32_3_13/ibi09313.htm